Lowenstein’s representation of Spring Bank Pharmaceuticals, Inc. in its definitive share exchange agreement with F-star to combine as F-star Therapeutics, Inc. is reported in Canada Stock Watch. The Lowenstein deal team included John D. “Jack” Hogoboom, Daniel C. Porco, and Madeline Roe (Corporate); Brian A. Silikovitz and Kristin V. Taylor (Tax); Robert J. Paradiso (Patent Counseling & Prosecution); and Andrew E. Graw and Christine Osvald-Mruz (Executive Benefits & Executive Compensation). View Lowenstein's news announcement about this transaction.